Federal Circuit Denies Sarepta’s Rehearing Bid, Upholding Penn’s Gene Therapy Patent
The Federal Circuit on Wednesday denied Sarepta Therapeutics Inc.’s petition for a rehearing regarding a panel decision that reinstated a gene therapy patent held by the University of Pennsylvania. This patent is notably licensed by Regenxbio Inc., highlighting ongoing complexities in biotechnology patent disputes. The decision marks another chapter in the evolving landscape of gene…